Isoliquiritigenin protects against angiotensin II-induced fibrogenesis by inhibiting NF- κB/PPARγ inflammatory pathway in human Tenon's capsule fibroblasts.

CONCLUSION: ISL could alleviate ANG II-induced fibrogenesis by inhibiting the NF-κB/PPARγ inflammatory pathway. In addition, ISL may be a potential agent for the treatment of conjunctival fibrosis. Most importantly, the NF-κB/PPARγ signaling pathway could be an effective therapeutic target for the prevention and treatment of conjunctival fibrosis after glaucoma surgery.
PMID: 32726604 [PubMed - as supplied by publisher]

Source: Experimental Eye Research - July 25, 2020 Category: Opthalmology Authors: Ye H, Xi Y, Chen X, Shen L, Le R Tags: Exp Eye Res Source Type: research